AER THERAPEUTICS
Aer Therapeutics is a clinical-stage biopharmaceutical company that develops an approach to treat lung disease with excess mucus and mucus plugs. The company focuses on treating respiratory diseases with significant unmet needs, such as COPD, cystic fibrosis, and asthma.
AER THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2014-01-01
Address:
Raleigh, North Carolina, United States
Country:
United States
Website Url:
http://www.aertherapeutics.com
Total Employee:
1+
Status:
Active
Total Funding:
36 M USD
Technology used in webpage:
Google Maps U.S. Server Location
Similar Organizations
Carisma Therapeutics
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Crinetics Pharmaceuticals
Crinetics is a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics.
Eikon Therapeutics
Eikon Therapeutics is a biopharmaceutical company that develops live-cell resolution microscopy and engineering for drug discovery.
Eureka Therapeutics
Eureka Therapeutics is a biotechnology company focusing on immunotherapies for the treatment of cancer.
Immune-Onc Therapeutics
Immune-Onc Therapeutics is a newly established biopharmaceutical company that develops therapeutic antibodies for cancer treatment.
Latigo Biotherapeutics
Operator of a drug discovery company intended to develop novel, non-opioid therapies for chronic pain.
OnKure Therapeutics
OnKure is a biotechnology company that commercializes a new cancer therapy based on novel, less toxic kinase inhibitor drugs.
Silk Road Medical
Silk Road Medical provides research and development services of medical devices for neurovascular diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
Hatteras Venture Partners
Hatteras Venture Partners investment in Series A - Aer Therapeutics
Canaan Partners
Canaan Partners investment in Series A - Aer Therapeutics
OrbiMed
OrbiMed investment in Series A - Aer Therapeutics
Official Site Inspections
http://www.aertherapeutics.com Semrush global rank: 5.69 M Semrush visits lastest month: 1.24 K
- Host name: 58.0.153.160.host.secureserver.net
- IP address: 160.153.0.58
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "Aer Therapeutics"
About - Aer Therapeutics
Our mission is to advance the treatment paradigm for mucus mediated lung diseases. Aer Therapeutics is a clinical-stage biopharmaceutical company dedicated to delivering a …See details»
Aer Therapeutics - Crunchbase Company Profile & Funding
Aer Therapeutics, a clinical-stage biopharmaceutical company developing therapeutic solutions for muco-obstructive lung diseases.See details»
Aer Therapeutics, Inc. - LinkedIn
Aer Therapeutics, Inc. | 913 followers on LinkedIn. Targeting mucus to improve lung health | Aer Therapeutics is a clinical stage biopharmaceutical company developing a novel inhaled approach to ...See details»
Aer Therapeutics - PitchBook
Information on valuation, funding, cap tables, investors, and executives for Aer Therapeutics. Use the PitchBook Platform to explore the full profile.See details»
Aer Therapeutics - VentureRadar
Aer Therapeutics, a clinical-stage biopharmaceutical company developing therapeutic solutions for muco-obstructive lung diseases. Aer-01 is a novel inhaled best-in-class therapeutic …See details»
Aer Therapeutics, Inc. - ContactOut
Aer Therapeutics is a clinical stage biopharmaceutical company developing a novel inhaled approach to treat lung disease with excess mucus and mucus plugs. We are focused on …See details»
Aer Therapeutics Company Profile - Office Locations ... - Craft
Aer Therapeutics has 5 employees at their 1 location and $36 m in total funding,. See insights on Aer Therapeutics including office locations, competitors, revenue, financials, executives, …See details»
Aer Therapeutics | North Carolina Biotech Center
Aer Therapeutics is a clinical stage biopharmaceutical company developing a novel inhaled approach to treat lung diseases with excess mucus and mucus plugs.See details»
Our Science - Aer Therapeutics
Mucus Dysregulation in COPD and Asthma Causes Mucus Plug Formation and Airway Obstruction The airways of the lungs are protected from environmental injury by a mucus gel comprised of mucin glycoproteins (“mucins”).1-7 In …See details»
Irish-founded Aer Therapeutics raises $36m for COPD …
Apr 14, 2023 Founded by researchers based in UCD and San Francisco, Aer is developing a novel drug to help COPD patients breathe easier.See details»
Aer Therapeutics - Overview, News & Similar companies
View Aer Therapeutics (aertherapeutics.com) location in North Carolina, United States , revenue, industry and description. Find related and similar companies as well as employees by title and …See details»
Aer Therapeutics - VentureRadar
DANISH BIOTECH is a trade organization for Danish biotech companies with the aim to promote opportunities for biotechnology research, development and production in Denmark and …See details»
Aer Therapeutics, Inc. | BioPharm America
Aer Therapeutics is a clinical-stage biopharmaceutical company dedicated to delivering a therapeutic solution to patients suffering from muco-obstructive lung diseases. Our initial focus …See details»
Aer Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials
Explore Aer Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, 2 news, Technology Platform:Small molecule drug, Drug ...See details»
Aer Therapeutics Closes $36 Million Series A to Advance …
Apr 13, 2023 /PRNewswire/ -- Aer Therapeutics, a biopharmaceutical company developing novel inhaled treatments for muco-obstructive lung diseases, today announced the...See details»
Aer Therapeutics CEO and Key Executive Team | Craft.co
Aer Therapeutics's Vice President, Research and Development is Irina Gitlin. Other executives include Blair Capel, Director of Finance; Thomas P. Mathers, Independent Director and 3 …See details»
Press Releases - Aer Therapeutics
April 13, 2023 Aer Therapeutics Closes $36 Million Series A to Advance Development of AER-01, an Innovative Mucolytic for the Treatment of Lung Diseases Supported by premier life science …See details»
News & Publications - Aer Therapeutics
Apr 6, 2023 Aer Therapeutics Closes $36 Million Series A to Advance Development of AER-01, an Innovative Mucolytic for the Treatment of Lung Diseases Supported by premier life science …See details»
News & Publications - Aer Therapeutics
Apr 13, 2023 Supported by premier life science industry investors Canaan, OrbiMed, and Hatteras Venture Partners. Proceeds to advance AER-01 into the clinic for treatment of …See details»